Comment period closes on the FDA proposal to end GLP-1 compounding at outsourcing facilities

The public comment period on the FDA's proposal to keep semaglutide, tirzepatide and liraglutide off the 503B Bulks List closed at 11:59 p.m. Eastern on July 30, 2026 ^[5]. The agency is reviewing what it received and has announced no date for a decision ^[5]. As of September 14, 2026, no final determination had been published.

The underlying notice appeared in the Federal Register on May 1, 2026 (91 FR 23431), under Docket No. FDA-2018-N-3240 ^[1]. On June 26, the FDA published a two-page extension notice (91 FR 38719) pushing the deadline to July 30 ^[1]. According to one clinic's summary of the docket, industry groups had asked for 60 additional days and received 30, moving the deadline from June 30 to July 30 ^[3]. The regulations.gov docket includes FDA staff evaluations for tirzepatide and liraglutide among its supporting documents ^[1].

Sources describe the scope slightly differently. The Federal Register listing and a compounding pharmacy's own analysis frame the April–May action as targeting semaglutide and tirzepatide ^[1][4], while other write-ups of the May notice include liraglutide as well ^[3]. One pharmacy site also dates the proposal to April 30, 2026, with comments through June 29 ^[4], which does not match the Federal Register's May 1 publication and original comment date ^[1]. Readers weighing coverage should note that the official docket dates are the ones in the Federal Register.

What a 503B exclusion would and would not do

There are two compounding pathways. A 503A pharmacy compounds for an individual patient with a specific prescription; a 503B outsourcing facility makes large batches without patient-specific prescriptions and ships at scale ^[3][4]. That bulk model is what made high-volume telehealth GLP-1 subscriptions possible ^[3]. The proposal, if finalized, would close the 503B route for these molecules but would not by itself eliminate the narrower 503A pathway, which requires documented clinical need such as an excipient allergy or a dosage form that is not commercially available; cost alone is not a recognized basis ^[4].

The proposal follows a long enforcement sequence. The FDA declared the semaglutide shortage resolved in February 2025 and set cutoffs of April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B facilities to stop making "essentially a copy" of the drug ^[4]. Warning letters followed in waves, including roughly 50 or more in March 2026 ^[4] and 25 during the week of June 15, 2026 ^[3].

Safety tallies differ across sources. One account cites more than 455 adverse event reports tied to compounded semaglutide and more than 320 tied to compounded tirzepatide as of early 2025 ^[3]; another cites 520 reports for compounded semaglutide as of April 30, 2025 ^[4]. Both attribute many reports to dosing errors, including patients drawing 5 to 20 times the intended amount because of confusion between "units" and mg/mL in multi-dose vials ^[4].

Separately, a narrative review titled "Multisystem Benefits of GLP-1 Microdosing" was published in Cureus ^[2]. The full text was not available in the material reviewed here, so its specific findings and limitations are not yet known from these sources.

Why it matters for patients

Nothing about the legal status of compounded GLP-1s changed on July 31; the exclusion remains a proposal until the FDA finalizes it ^[3]. But if it is finalized, the bulk supply that feeds most large compounded semaglutide programs would narrow from the top ^[3].

Price is the practical issue. Compounded semaglutide has typically run $150 to $400 a month, against $935 to $1,349 a month for brand-name Ozempic or Wegovy without insurance ^[4]. One counterweight: oral Wegovy (semaglutide) was approved December 22, 2025 and is listed at $149 a month without insurance, with trial participants losing about 17 percent of body weight versus 2.7 percent on placebo ^[3].

What happens next

The FDA has not published a timeline for finalizing the determination ^[5]. Some industry analysts expected a final rule in the third quarter of 2026 ^[4], but that had not occurred as of mid-September. Until then, the docket record and the agency's eventual response are the documents to watch.